Biotech Values

[biomaven0]

>Exon 17 mutations in GIST

My concern here is that very few exon 17 mutations are found prior to TKI therapy. According to this site, of the order of 1.5% :

http://www.gistsupport.org/about-gist/mutation-analysis-kit-and-pdgfra.php

So the question becomes what happens if pona is used on these patients from the outset? Pona is about 10x more potent than Gleevec on wild-type KIT, more so on mutated KIT. So we may see these mutations never developing in the first place. (The difference between pona and dasatinib or sorafenib or Sutent is less - about a factor of 2). I haven't really followed current GIST treatment guidelines - not sure what the current SOC is.

(BTW, I have no idea if pona would be effective against the exon 17 mutations - quite possibly not).

Peter